Prospan Hustensaft

Quick links to important sections

Prospan Hustensaft

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Prospan Hustensaft

Quick Facts

Property Description
Active Ingredient Ivy leaf dry extract (Hedera helix folium)
Form Syrup (Hustensaft), a liquid solution
Pharmacological Class Phytopharmaceutical (Herbal medicinal product)
General Purpose To promote a productive cough and clear airways
Origin Natural origin (plant-derived)

What Type of Medicine is Prospan Hustensaft? (Identity and Classification)

Prospan Hustensaft is classified as a modern phytopharmaceutical or herbal medicinal product, meaning its active ingredient is a standardized extract derived from a natural origin plant source. This preparation, manufactured by Engelhard Arzneimittel, is formulated as a syrup (Hustensaft), which is a liquid solution intended for oral administration, and is available as an Over-The-Counter (OTC) medicine. The use of Ivy leaf dry extract as an expectorant has an established role in traditional and complementary medicine.

Composition: The Active Ingredient and Natural Origin

The sole active ingredient in Prospan Hustensaft is the Ivy leaf dry extract (Hedera helix folium), sourced from the Climbing Ivy plant. This extract is rich in triterpene phytochemicals, specifically saponins like Hederacoside C, which are the components identified as mediating the medicine’s biological effects. This active compound, Hederacoside C, and its related compounds are recognized for their pharmacological activity. The extract is standardized to ensure a consistent concentration of these saponins across batches, utilizing an aqueous solution as the delivery vehicle.

General Purpose and High-Level Function

The general purpose of Prospan Hustensaft is to assist the body's natural processes of clearing the airways, primarily by promoting a productive cough. This effect is achieved through a recognized dual high-level function: the preparation acts as a secretolytic, thinning the thick mucus and phlegm, and as a bronchospasmolytic, helping to relieve tension and constriction in the smooth muscles of the bronchial tubes. This combined action helps the individual effectively mobilize and expel accumulated secretions, contributing to the general relief of symptoms associated with catarrhal diseases of the respiratory tract.

What side effects are possible with Prospan Hustensaft?

Possible Side Effects and Safety Information

The safety profile for preparations containing Ivy leaf dry extract is established through regulatory assessments that classify reported adverse reactions by frequency and the body system affected. All documented information is based strictly on government regulatory documents, such as those from the European Medicines Agency (EMA) and national health authorities.


Official Adverse Reaction Classification

The officially documented adverse effects for this phytopharmaceutical are categorized into two primary systems, reflecting findings from post-marketing surveillance and clinical data:

  • Gastrointestinal Disorders: Effects such as nausea, vomiting, and diarrhea are typically classified as uncommon adverse reactions.
  • Immune System Disorders: Manifestations of hypersensitivity or allergic reactions, which may include urticaria (hives), rash, or dyspnoea (shortness of breath), are officially classified as rare events.

Safety Restrictions and Considerations

The primary safety limitation is defined by the medicine's contraindication in individuals with a known hypersensitivity to the active substance (Hedera helix folium) or any of the other components.

Regarding specific populations, the regulatory stance on use during pregnancy and lactation is that it is generally not recommended due to a lack of sufficient data. Furthermore, official safety documents specify that the presence of certain excipients may constitute a safety restriction for individuals with rare hereditary problems of fructose intolerance. Patients experiencing a cough that persists for more than two to three weeks or those who develop symptoms such as shortness of breath, fever, or purulent sputum require a formal medical assessment.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Prospan Hustensaft is strictly defined by the documented manifestations that occur when the medicine is administered at substantially high doses. The regulatory threshold for classifying an overdose risk is specifically defined as taking more than three times the recommended maximum daily dose.


Documented Overdose Manifestations

Overdose may present as an intensification of known side effects, affecting the gastrointestinal system and potentially the central nervous system. Officially documented signs resulting from a substantially large dose include:

  • Gastrointestinal Effects: Nausea, vomiting, and diarrhea.
  • Systemic Effects: Feeling excitable or experiencing excitement.

Emergency Action and Management

The regulatory documentation mandates specific action when the overdose threshold is exceeded. Immediate medical advice is required in this scenario, and the official guidance directs users to consult a doctor, pharmacist, or qualified healthcare practitioner. The documented management strategy for this medicine is symptomatic and supportive treatment. This approach is specified because official documents explicitly state that no specific antidote is known for Ivy leaf dry extract overdose. The documented guidance for overdose applies uniformly, as there are no population-specific notes regarding severity or manifestations.

Therapeutic Uses of Prospan Hustensaft

The active ingredient in this medication is commonly used to help with symptoms related to the respiratory system, and is applied in addressing symptoms related to coughs that are productive.


This medicine is commonly used across conditions associated with acute or disruptive episodes of bronchial inflammation, and is considered relevant in conditions involving recurrent or episodic manifestations such as certain forms of chronic bronchial disease. It may assist with symptom clusters of thick mucus, expectoration difficulties, and airway irritation. The primary benefit supports the patient during difficult episodes by easing distress related to inefficient coughing, which contributes to improved comfort during symptomatic periods.

“The medicine is relevant for easing symptoms that interfere with daily functioning and is often used during phases when symptoms become more noticeable.”

Quick Fact: Relief for Productive Cough

Symptom Domain Key Benefit
Thick Mucus / Phlegm Supports the management of symptoms linked to organ-specific functional stress and easing distress.
Expectoration Difficulty Supports the management of symptoms related to physical discomfort.
Airway Irritation Contributes to improved comfort and helps maintain a sense of stability when symptoms are more noticeable.

Eligibility and Restrictions for Use

Eligibility and Contraindications (Official Regulatory Information)

Patient eligibility for Prospan Hustensaft is strictly defined by regulatory documents, focusing on age restrictions, pre-existing conditions, and known sensitivities. The medicine is generally permitted for Adults and Adolescents (12 years and over) and Children (2 years and older).

Absolute Non-Eligibility (Contraindications)

The medicine is formally contraindicated and must not be used by the following patient groups:

  • Individuals with a known hypersensitivity or allergy to the active ingredient, Ivy leaf dry extract, plants of the Araliaceae family, or any other excipients.
  • Children under 2 years of age due to the specific risk of potentially aggravating respiratory symptoms in this age group.
  • Patients with diagnosed rare hereditary fructose intolerance (HFI), as the syrup contains sorbitol which is metabolized into fructose.

Restricted or Conditional Use

Certain populations require caution or medical consultation before use:

  • Infants under 1 year of age should only use the syrup after consulting a doctor.
  • Patients with a history of gastritis or gastric ulcer are advised to use the medicine with caution, as stated in official labeling.

Pregnancy and Lactation Status

Use during pregnancy and breastfeeding is not recommended. This restriction is based on the official regulatory stance that safety has not been established due to a lack of sufficient clinical data in these populations.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation for Prospan Hustensaft (Ivy leaf dry extract) states that no clinical studies have been performed to investigate the effects of the product on other medicinal products.

Consequently, the regulatory profile is defined by a general absence of known interactions established through clinical reporting or formal pharmacokinetic studies.


Pharmacodynamic Interaction Restriction

Despite the general lack of documented interactions, regulatory authorities, including those in Europe, have noted one specific restriction concerning pharmacodynamic effects.

Co-administration with opiate antitussives is officially advised to be not recommended without consultation with a healthcare professional. This restriction primarily concerns substances such as Codeine or Dextromethorphan due to potential additive effects on cough suppression.

Interaction Type Interacting Substance/Product Official Regulatory Status
Pharmacodynamic Restriction Opiate Antitussives (Codeine, Dextromethorphan) Not recommended without professional guidance
Pharmacokinetic Data All medicinal products No studies performed / No interactions known

This single, explicit restriction establishes the only formal constraint noted in the official labeling. No requirements for timing separation (e.g., administering doses hours apart), food interactions, or alcohol restrictions are documented in the product's regulatory interaction section.

Mechanism of Action

Modulation of beta2-Adrenergic Receptor Function

The mechanism of Prospan Hustensaft centers on the saponin alpha-Hederin, which targets the beta2-Adrenergic Receptors (beta2AR) and the regulatory enzyme GRK2 in the airways. By inhibiting GRK2, the mechanism prevents the phosphorylation and subsequent desensitization of beta2ARs. This functional potentiation maintains the cells' responsiveness to endogenous catecholamines, which increases cAMP levels, initiating the downstream signaling cascade.

Dual Cascade for Secretolysis and Muscle Tone

The resulting increase in cAMP acts on two distinct cell types: stimulating the release of pulmonary surfactant from alveolar cells and simultaneously reducing intracellular calcium (Ca^2+) in bronchial smooth muscle. Surfactant release produces the secretolytic effect by decreasing mucus viscosity, while the Ca^2+ reduction causes a reduction in the contractile state of bronchial smooth muscle (bronchospasmolysis). This dual cascade results in the physiological modification of secretion viscosity and bronchial muscle tone.

Mechanistic Constraint

This modulatory action is strictly constrained as it relies on the availability of the body’s endogenous ligands for beta2AR activation. The mechanism operates as a functional modulator, not a direct agonist.

Dosage and Administration Information

The use of Ivy leaf dry extract syrup, such as Prospan Hustensaft, follows standardized administration protocols to ensure proper use. This medicine is intended for oral administration as a liquid solution. The administration of the medicine is typically performed independently of mealtimes and is taken undiluted.

The dosing regimen is based on age, requiring precise measurement for each intake. For adolescents (12 years and older) and adults, the standard single dose volume is generally 5 mL to 7.5 mL of syrup. This volume is administered in a divided frequency of three times per day.

For pediatric use, volumes are adjusted according to age category: children aged 6 to 11 years are typically administered a single dose of 5 mL, while children aged 2 to 5 years receive 2.5 mL. These smaller doses are generally given two to three times per day. Use in children under two years old is not advised unless specifically consulted with a healthcare professional.

Procedurally, the preparation requires the bottle to be shaken well prior to use. The dose must be measured accurately using the enclosed dosing device. The overall treatment course defines a minimum duration of at least one week. Furthermore, the regimen instructs continuation for an additional two to three days after the clinical resolution of symptoms. In the event of a forgotten dose, a double dose must not be taken to compensate.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Prospan Hustensaft (Ivy Leaf Extract)


Evidence for Use in Acute Cough and Bronchitis Symptoms

The ivy leaf extract was studied for use in conditions associated with acute or disruptive episodes of cough and symptoms of acute bronchitis. The evidence here largely comes from short-term Randomized Controlled Trials (RCTs), where subjects received the extract or a comparator over a defined time interval. Studies monitored outcomes related to physical discomfort, measuring changes in symptom severity scores (like the Bronchitis Severity Score, or BSS) and patient-reported measures such as cough frequency. Findings indicate patterns related to how symptoms evolved over typical short-term periods of about seven days.


Evidence for Chronic Conditions and Special Populations

Research has also explored whether the extract affects outcomes in conditions characterized by fluctuating or episodic manifestations, such as certain chronic bronchial conditions. This evidence includes Controlled Clinical Trials and large-scale observational studies. The extract was studied for use in a wide range of individuals, including both adults and children (including infants). However, certainty remains low compared to evidence for acute cough, and the results apply only to the populations studied.


Research Gaps and What is Still Uncertain

The majority of research focuses on short-term symptom changes; therefore, follow-up durations were limited, typically lasting seven to 14 days. Long-term effects are not fully established, and there is limited information tracking the durability of response or the long-term patient experience. The existing research presents limitations: evidence quality varies across studies, sample sizes were modest, and comparative evidence remains insufficient in several areas. Research provides context on group patterns, not individual predictions.

Key Studies & References

  1. Ivy leaf (Hedera helix) for acute upper respiratory tract infections: an updated systematic review
  2. The Impact of Ivy Leaf Dry Extract EA 575 on Subsequent Antibiotic Use and Its Therapeutic Value in Children and Adolescents with the Common Cold: A Retrospective Prescription Database Analysis
  3. Efficacy and Safety of a Single Ivy Extract Versus Two Herbal Extract Combinations in Patients with Acute Bronchitis: A Multi-Center, Randomized, Open-Label Clinical Trial (focusing on BSS)
  4. Phytotherapy for acute respiratory tract infections in children: a systematically conducted, comprehensive review

Frequently Asked Questions (FAQ)

Common questions about Prospan Hustensaft (FAQ)


Q: Does Prospan Hustensaft contain alcohol?

A: According to the official product information, the Ivy leaf extract used in this medicine is obtained using a solution of 30% ethanol (alcohol) as the extraction solvent. Residual amounts of alcohol may be present in the final syrup.

Q: Does Prospan Hustensaft contain sugar?

A: Official regulatory documents confirm that Prospan Hustensaft does not contain sugar. It is sweetened with the sugar substitute sorbitol solution, which is one of the non-medicinal ingredients (excipients).

Q: How long does it typically take for the effects of Prospan Hustensaft to be noticeable?

A: Studies and official information indicate that a statistically significant improvement in cough severity scores may have begun to be observed as early as treatment day 3. However, individual patient experience may vary.

Q: Can Prospan Hustensaft be taken long-term?

A: Official guidelines recommend seeking consultation with a doctor or pharmacist if symptoms worsen or do not improve after 1 week. Research indicates that data on long-term effects are limited as most studies focus on short-term symptom changes.

Q: What is the maximum number of days I can take Prospan Hustensaft?

A: The product labeling advises seeking medical advice if the cough persists or symptoms have not improved after one week. This indicates the period after which medical advice should be sought if symptoms have not improved.

Q: Can Prospan Hustensaft be used for all types of coughs?

A: According to the official regulatory description, the medicine is intended for the symptoms of respiratory disorders that are associated with the excessive formation of thick mucus. It is specifically indicated for use to promote a productive, or 'chesty,' cough.

Q: What are the most serious possible side effects listed for Prospan Hustensaft?

A: Regulatory documents classify the most serious possible side effects as rare immune system disorders. These involve hypersensitivity or allergic reactions, which may include manifestations like a rash, hives (urticaria), or severe breathing difficulty (dyspnoea).

Q: Can Prospan Hustensaft interact with blood thinners?

A: Regulatory documents state that no formal clinical studies have been performed to investigate the product’s effect on other medicinal products, including blood thinners. As no formal studies have been conducted, there is an absence of known interactions reported so far.

Q: Are there any known interactions between Prospan Hustensaft and common cold medicines?

A: Official regulatory information states that no formal clinical studies have been performed on interactions with common cold medicines. As no formal studies have been conducted, there is an absence of known interactions reported so far.

Q: Can I take Prospan Hustensaft if I have diabetes?

A: The official product leaflet provides information for individuals with diabetes, stating that each 5 mL dose contains 1.9 grams of sorbitol. This amount is equivalent to 0.08 bread units (BU).

Q: What is the main difference between Prospan Hustensaft and other ivy leaf extracts?

A: The preparation uses the standardized Special Ivy Extract EA 575®. The manufacturer states that this extract is produced through a specific, defined manufacturing process, which distinguishes it from other ivy leaf extracts.

Q: Does Prospan Hustensaft cause drowsiness?

A: Drowsiness is not listed as a reported common, uncommon, or rare side effect in the official regulatory documents describing adverse reactions for the product.

Q: Is it normal to feel a change in taste after taking Prospan Hustensaft?

A: Change in taste is not listed as a common, uncommon, or rare adverse reaction in the official regulatory documents.

Q: What is the extract ratio of the ivy leaf used in Prospan Hustensaft?

A: The official composition details state that the dry extract from ivy leaf has a drug to extract ratio of 5 to 7.5 parts of crude drug to 1 part of extract. This ratio ensures a consistent concentration of the extract.

Q: Are there any special dietary restrictions when taking Prospan Hustensaft?

A: The official labeling indicates that the medicine is typically administered independently of mealtimes. The regulatory documents do not specify any requirements for timing separation between the dose and food consumption.

Q: Where is the research evidence for Prospan Hustensaft typically published?

A: The evidence supporting the use of the extract is drawn primarily from Randomized Controlled Trials (RCTs) and Observational Studies. These studies are typically published in medical and scientific literature and have been reviewed by authoritative bodies.

Q: Has Prospan Hustensaft been approved by major regulatory bodies like the EMA or FDA?

A: Prospan Hustensaft is a cough remedy authorized by the European Medicines Agency (EMA). Official regulatory documents from European sources do not contain information regarding approval status by the U.S. Food and Drug Administration (FDA).

Q: Does Prospan Hustensaft contain any common allergens?

A: The official safety documents indicate a risk of hypersensitivity (allergic reactions) to the active substance or any of the other components in the syrup. The labeling does not provide a comprehensive list of common food allergens, but advises caution for known sensitivities.

Q: Is Prospan Hustensaft gluten-free?

A: According to the official regulatory list of ingredients (excipients), gluten-containing materials are not listed as ingredients in the syrup’s regulatory composition.

Q: Is the preparation method of the ivy leaf extract in Prospan Hustensaft unique?

A: The extract used in the medicine is the standardized Special Ivy Extract EA 575®. The manufacturer uses this name to denote its preparation through a specific, defined manufacturing process.

Q: Does Prospan Hustensaft affect the ability to drive or operate machinery?

A: The official regulatory safety information contains no explicit warning or statement regarding any known effects of the medicine on the ability to drive or operate machinery. Drowsiness is not listed as a common side effect.

Q: Is there a risk of overdose with Prospan Hustensaft?

A: The official labeling describes the possibility of an overdose. Overdose symptoms can include nausea, vomiting, and diarrhea. The product labeling specifies that a healthcare professional must be consulted immediately if an overdose is suspected.

Q: What makes Prospan Hustensaft different from an expectorant?

A: The official description of the medicine's function highlights two properties: a mucolytic action, which loosens stuck mucus, and a bronchodilator action, which relaxes the smooth muscles of the bronchial tubes. This dual action is an important part of its overall effect.

Q: Why are there different versions of Prospan (e.g., syrup, drops, lozenges)?

A: Regulatory studies and documentation for the active ingredient acknowledge that different formulations of ivy leaf extract (including syrups, drops, and lozenges) have been used in clinical research and are available in various markets.

Q: Are there any specific warnings for people with respiratory diseases?

A: The official product labeling states that a healthcare professional must be consulted if additional or worsening symptoms occur during use. These concerning symptoms include the development of shortness of breath, fever, or purulent/bloody sputum.

Q: Can Prospan Hustensaft be taken at the same time as pain relievers?

A: Regulatory documents confirm that no formal clinical studies have been performed to investigate the product’s effect when taken with common pain relievers. As no formal studies have been conducted, there is an absence of known interactions reported so far.

Q: Does Prospan Hustensaft interact with herbal supplements?

A: Regulatory documents state that no formal clinical studies have been performed to investigate the product’s effect when taken with other herbal supplements. As no formal studies have been conducted, there is an absence of known interactions reported so far.

Q: What is the difference between Prospan Hustensaft and a mucolytic?

A: The official product description indicates that the medicine functions as a mucolytic, meaning it loosens stuck mucus. However, it also has a bronchodilator effect, which relaxes the bronchial tubes. This dual action is an important part of its overall effect.

How should Prospan Hustensaft be stored and disposed of?

How to Store and Dispose of Prospan Hustensaft?

Prospan Hustensaft must be stored under specific environmental and safety conditions defined by regulatory labeling. The medicine should be stored below 25 C to maintain its required stability. It must also be kept out of the reach and sight of children at all times.

Stability and Handling

Once the bottle has been opened for the first time, the syrup must be used within a period of 3 months. The product must not be used beyond the expiry date indicated on the packaging.

Disposal Requirements

Expired or unused medicine should not be disposed of via wastewater (sinks or toilets) or as standard household trash. Patients are instructed to consult their pharmacist to determine the appropriate local procedures for disposing of pharmaceutical waste, ensuring environmental protection compliance.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Prospan Hustensaft found in:

A-Z Index: